Yap TA - Search Results

1

Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.

Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, Yap TA, Molife LR, Kaye SB, de Bono JS, Banerji U. Rafii S, et al. Among authors: yap ta. Clin Cancer Res. 2015 Apr 15;21(8):1869-76. doi: 10.1158/1078-0432.CCR-14-2424. Epub 2015 Feb 3. Clin Cancer Res. 2015. PMID: 25649020 Free PMC article.

2

Adjuvant therapy of renal cell carcinoma.

Yap TA, Eisen TG. Yap TA, et al. Clin Genitourin Cancer. 2006 Sep;5(2):120-30. doi: 10.3816/CGC.2006.n.028. Clin Genitourin Cancer. 2006. PMID: 17026800 Review.

3

Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.

Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS. Haluska P, et al. Among authors: yap ta. Clin Cancer Res. 2007 Oct 1;13(19):5834-40. doi: 10.1158/1078-0432.CCR-07-1118. Clin Cancer Res. 2007. PMID: 17908976 Clinical Trial.

4

Targeting CYP17: established and novel approaches in prostate cancer.

Yap TA, Carden CP, Attard G, de Bono JS. Yap TA, et al. Curr Opin Pharmacol. 2008 Aug;8(4):449-57. doi: 10.1016/j.coph.2008.06.004. Epub 2008 Jul 28. Curr Opin Pharmacol. 2008. PMID: 18619560 Review.

5

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Attard G, et al. Among authors: yap ta. J Clin Oncol. 2008 Oct 1;26(28):4563-71. doi: 10.1200/JCO.2007.15.9749. Epub 2008 Jul 21. J Clin Oncol. 2008. PMID: 18645193 Clinical Trial.

6

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.

Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Yap TA, et al. Curr Opin Pharmacol. 2008 Aug;8(4):393-412. doi: 10.1016/j.coph.2008.08.004. Epub 2008 Aug 27. Curr Opin Pharmacol. 2008. PMID: 18721898 Review.

7

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.

Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, DeBono JS. Vidal L, et al. Among authors: yap ta. Clin Cancer Res. 2008 Nov 1;14(21):7127-37. doi: 10.1158/1078-0432.CCR-08-0524. Clin Cancer Res. 2008. PMID: 18981012 Clinical Trial.

8

Reovirus therapy in cancer: has the orphan virus found a home?

Yap TA, Brunetto A, Pandha H, Harrington K, Debono JS. Yap TA, et al. Expert Opin Investig Drugs. 2008 Dec;17(12):1925-35. doi: 10.1517/13543780802533401. Expert Opin Investig Drugs. 2008. PMID: 19012507 Review.

9

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Fong PC, et al. Among authors: yap ta. N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24. N Engl J Med. 2009. PMID: 19553641 Free article. Clinical Trial.

10

Targeting the PI3K/AKT pathway for the treatment of prostate cancer.

Sarker D, Reid AH, Yap TA, de Bono JS. Sarker D, et al. Among authors: yap ta. Clin Cancer Res. 2009 Aug 1;15(15):4799-805. doi: 10.1158/1078-0432.CCR-08-0125. Epub 2009 Jul 28. Clin Cancer Res. 2009. PMID: 19638457 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters